4 results
Approved WMOCompleted
· To evaluate the effect of zibotentan anddapagliflozin in combination and alone versusplacebo on UACR.
Approved WMOPending
The main objective of this Phase IIa/b study is to demonstrate the effectof zibotentan on HVPG, and that dapagliflozin can mitigate fluid retention safety concernsregarding its use in this population.
Approved WMORecruiting
Compare the clinical efficacy of Epcoritamab to SOC (R-GemOx or BR)
Approved WMORecruiting
Part 1: dose safety confirmationPrimary: To evaluate the proportion of participants with TRAEs leading to discontinuation within 12 weeks after the first dose of nivolumab plus2 different dose levels of relatlimab (360 mg and 720 mg) in combination…